Syndesi Therapeutics joins the JLINX community
Johnson & Johnson Innovation, JLINX
Bioqube ventures has one mission: bringing early-stage healthcare companies to the next level. Entrepreneurial, result driven, shoulder to shoulder.
Our team jointly represents over 40 years of leadership experience in identifying and funding promising scientific opportunities, is skilled in helping businesses grow and is deeply connected across corporate, government and academic research ecosystems.
We cut cost, accelerate business and bring value by linking three key components: access to capital, specialized infrastructure and expertise.
In 2016, Bioqube Ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to act as the independent management arm leading the new Johnson & Johnson Innovation, JLINX initiative. Through this partnership, Bioqube Ventures will run the day to day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying, securing and investing in new companies, and supporting the overall scale-up of the new initiative.
Our partnership with Johnson & Johnson Innovation – JLINX, is the embodiment of our mission: a multifaceted approach that enables early-stage healthcare companies to reach their full potential in a cost effective and time efficient way. Whether you are a scientist, entrepreneur or venture capitalist, Bioqube Ventures will face the challenge – working apart, and together with you.
Nico Vandervelpen is managing director and co-founder of Bioqube Ventures.
Nico previously served in a variety of capacities at LRM, a Belgium-based private equity and venture capital firm, including most recently as the funds Chief Operating Officer. Prior to joining LRM, between 1998 and 2007, Nico was a senior executive at Ernst & Young.
Nico served on the board of directors of several public and private life sciences companies and has led several dozen international venture capital transactions and M&A deals including Minerva Neurosciences (Nasdaq: NERV), Tigenix (NYSE Euronext: TIG), SEPS Pharma (acquired by Amatsi) and Apitope.
Nico holds a Masters degree in commercial and business engineering from Hasselt University as well as a Master in Accountancy from VLEKHO Business School - Brussels.
Debora Dumont is managing director and cofounder of Bioqube Ventures.
Debora previously served as Head of Health & Care at LRM, a Belgium-based private equity and venture capital firm. In this position, she served as a board member on several biotech companies and was involved in a series of international venture capital transactions including XO1 (acquired by Johnson & Johnson), FFPharma, Complix and Therasolve. Prior to joining LRM, between 2007 and 2010, Debora was a business developer at the Biomedical Research Institute of Hasselt University and manager of the life sciences cluster organization LifeTechLimburg (now LifeTechValley).
Debora has a PhD in Biomedical Sciences from Hasselt University and holds a Masters degree in Bioscience Engineering from K.U. Leuven.
Tol Trimborn is a Venture Partner of Bioqube Ventures.
Tol has over 15 years of experience in the life sciences and venture capital industry. He is a highly motivated, creative and dynamic entrepreneur. Tol serves and has served in a variety of management capacities, including CEO of Arcarios, COO of Gadeta, founder and general manager at DNage (acquired by Pharming). He has co-founded several companies including Arcarios and Gadeta.
Tol started his career as a Postdoctoral fellow conducting scientific research at the prestigious Howard Hughes Medical Institute of Stanford, became a leader of the molecular biology activities at Kalobios, an early-stage biotech start-up in Mountain View and expanded his scientific network into a commercially oriented network as a biotech analyst at LSP, The Netherlands.
Tol has a PhD in Medical Biology at the Erasmus University Rotterdam, The Netherlands and holds Masters degrees in biology and chemistry from Leiden University, The Netherlands.
Dirk Reyn is a Venture Coach of Bioqube Ventures.
Dirk has over 30 years of experience in the life sciences industry. He has served in a variety of management capacities, including Global Business Unit leader for Gastroenterology, head of a Regulatory department and head of European Business development at JNJ, Founder and CEO of Movetis, Global Commercial lead at Shire, founder and CEO of Progress Pharma and founder of R&S consulting. He is currently CEO of ETheRNA, a spin-off from the University of Brussels with a breakthrough therapy for cancer. He is also board member of Tigenix and vice-chairman of Flandersbio, an organization of Flemish biotech companies.
Dirk Reyn is a Pharmacist and has an MBA from Handelshogeschool (Antwerpen)/Northwestern University (Kellog’s Chicago/USA).
Joris is a Venture Coach of Bioqube Ventures.
Joris has 15 years' experience in the pharma-biotech sector, shaping and directing innovative and collaborative R&D programs. As an independent advisor, Joris currently provides strategic R&D and funding advise to international biotech companies and acts as Director R&D at Facio Therapies. Previously, Joris had various roles of increasing responsibility in start-ups as well as in large international companies such as Johnson & Johnson, Movetis and Shire Pharmaceuticals, where in his most recent position he served as Director Discovery.
Joris holds a PhD in Medical Sciences from Ghent University and a Masters in Bioscience Engineering from the Catholic University of Leuven.
Olivier Houben is the Legal Counsel of Bioqube Ventures.
He is a partner of Value for Growth, an independent consulting group. Olivier assisted in the creation and development of start-ups, supported companies & organisations with strategy development and implementation and together with leading (investment) banks helped companies with their fund-raising. Main achievements include assisting with the legal aspects of the creation of the venture capital fund Vesalius Biocapital I & III, co-operating with leading (investment) banks on fund-raising and legal counsel for Selligent, a multinational company of Belgian origin that provides relationship marketing solutions.
Olivier holds a Master’s Degree in Law from University of Louvain & University of Antwerp, as well as Special Licence Tax Law from the University of Brussels.
Alexander is Business Analyst of Bioqube Ventures.
Alexander recently graduated from the University of Warwick with a Masters degree in Medical Biotechnology and Business Management and holds a Master Degree in Biomedical Sciences from Antwerp University.
Géry Dams is JLINX Operations Manager of Bioqube Ventures and responsible for the day-to-day general and lab facility management of the JLINX facilities at the Janssen R&D site in Beerse.
Géry started his career at Janssen in 1990 as a scientist in the department of Bacteriology & Mycology. In 1998, Géry joined Tibotec in the role of team-leader cellular biology. After Tibotec was acquired by Johnson and Johnson, Géry became Associate Director e-Biology, Associate Director Target Validation & Engagement and finally Associate Director hit-to-lead and lead optimization within different discovery capability organizations at Janssen. In October 2017, Géry’s hit-to-lead and Lead optimization team was acquired by Charles River labs.
Géry holds a Master in Biochemistry from Breda Technical University.
Eve is Office Manager & Communication Officer at Bioqube Ventures. She has experience in marketing, organisation and graphic design. She supports our JLINX community in their day-to-day activities and is responsible for our communication efforts both internally and externally.
Eve has a Bachelor’s degree in Communication Management and attended Business School at the University of Greenwich. She holds a Master’s degree in Cultural Management from Antwerp University.
Johnson & Johnson Innovation’s mission is to identify the best science around the world to advance important therapies and products for patients and consumers. To support its mission, Johnson & Johnson is expanding its company incubation strategy with the launch of Johnson & Johnson Innovation, JLINX, an investment and incubation model, involving Bioqube Ventures as an external management team, hosted in a fully dedicated facility located on the Janssen Research & Development Campus in Beerse, Belgium.
JLINX complements and extends the Johnson & Johnson Innovation network of initiatives to create a unique environment for scientist entrepreneurs to access capital, infrastructure, resources and expertise needed to build their businesses and advance scientific research and development for the benefit of patients.
The power of the JLINX model lies in the ambition of trying to marry internal expertise with external entrepreneurial skills and hence creating a start-up culture with selected resources, insights and expertise of a global healthcare leader to accelerate breakthroughs.
Investment in promising transformative innovation through the JLINX initiative is venture-based and will not hold any specific rights to commercialized products. JLINX will launch with initial venture funding from Johnson & Johnson Innovation, JJDC (JJDC) with the aim to leverage these funds along with those from additional external investors.
Visit jlinx.jnjinnovation.com for more information about JLINX.
JLINX is supported by the European Union through the European Regional Development Fund and by the Flemish Government through Flanders Innovation & Entrepreneurship.
Syndesi Therapeutics joins the JLINX community
Rejuvenate Biomed joins the JLINX community
Nico Vandervelpen nominated in Bloomberg50 list
What's brewing at JLINX?
Dosing of First Patient with Octimet’s investigational agent OMO-1
eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship
ProteoFormiX and Clarity Genomics join the JLINX Community
1 year of JLINX
S-Biomedic joins the JLINX Community
Caelus Health joins the JLINX Community
Octimet Oncology joins the JLINX Community
eTheRNA joins the JLINX Community
"Pitch your Microbes" – Meet our winners: S-Biomedic and BioMillenia!!
Bioqube Ventures teams up with Johnson & Johnson Innovation, JLINX and Janssen Human Microbiome Institute - "Pitch Your Microbes" Competition
JLINX Science Meets Business Symposium
Watch event pictures
Bioqube Ventures expands team with Ventures Coaches
Meet the team
JLINX Launch Event – Sparking Life Science Innovation - Beerse Belgium
Johnson & Johnson Innovation Launches JLINX: A New Company Incubation Model Located at the Janssen Campus in Belgium
Bioqube ventures launches specialist investment firm and announces collaboration with Johnson & Johnson Innovation, JLINX